The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Prime Medicine Inc shares valued at $4,950,000 were purchased by GV 2021 GP, L.L.C. on Aug 01 ’25. At $3.30 per share, GV 2021 GP, L.L.C. acquired 1,500,000 shares. The insider’s holdings grew to 3,262,440 shares worth approximately $13.28 million following the completion of this transaction.
Also, NELSEN ROBERT purchased 3,030,300 shares, netting a total of over 9,999,990 in proceeds. Following the buying of shares at $3.30 each, the insider now holds 6,230,300 shares.
Before that, ARCH Venture Partners XII, LLC had added 3,030,300 shares to its account. In a trade valued at $9,999,990, the 10% Owner bought Prime Medicine Inc shares for $3.30 each. Upon closing the transaction, the insider’s holdings increased to 3,030,300 shares, worth approximately $25.36 million.
As published in a research note from Citigroup on May 27, 2025, Prime Medicine Inc [PRME] has been rated down from a Buy to a Neutral and the price target has been revised to $1.50. Analysts at JP Morgan downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in mid May. As of May 20, 2025, H.C. Wainwright has decreased its “Buy” rating to a “Neutral” for PRME. Earlier on December 10, 2024, JMP Securities initiated its rating. Their recommendation was “a Mkt outperform” for PRME stock.
Analyzing PRME Stock Performance
On last trading session, Prime Medicine Inc [NASDAQ: PRME] plunged -6.86% to $4.07. The stock’s lowest price that day was $4.015, but it reached a high of $4.36 in the same session. During the last five days, there has been a surge of approximately 3.83%. Over the course of the year, Prime Medicine Inc shares have dropped approximately -16.94%.
Is Prime Medicine Inc subject to short interest?
Stocks of Prime Medicine Inc saw a sharp rise in short interest on 2025-07-15 jumping by 3.18 million shares to 21.66 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 18.48 million shares. A jump of 14.69% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.98 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.98.
Which companies own the most shares of Prime Medicine Inc (PRME)?
In terms of Prime Medicine Inc share price expectations, FactSet research, analysts set an average price target of 17 in the next 12 months, up nearly 289.02% from the previous closing price of $4.37. Analysts anticipate Prime Medicine Inc stock to reach 23 by 2025, with the lowest price target being 12. In spite of this, 5 analysts ranked Prime Medicine Inc stock as Buy at the end of 2025. On May 20, 2024, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $10.
